These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26080652)

  • 1. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Pieber TR; Famulla S; Eilbracht J; Cescutti J; Soleymanlou N; Johansen OE; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Obes Metab; 2015 Oct; 17(10):928-35. PubMed ID: 26080652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
    Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
    Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
    Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
    Rosenstock J; Marquard J; Laffel LM; Neubacher D; Kaspers S; Cherney DZ; Zinman B; Skyler JS; George J; Soleymanlou N; Perkins BA
    Diabetes Care; 2018 Dec; 41(12):2560-2569. PubMed ID: 30287422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
    Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
    Famulla S; Pieber TR; Eilbracht J; Neubacher D; Soleymanlou N; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Technol Ther; 2017 Jan; 19(1):49-60. PubMed ID: 27929674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
    Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
    Kadowaki T; Haneda M; Inagaki N; Terauchi Y; Taniguchi A; Koiwai K; Rattunde H; Woerle HJ; Broedl UC
    Adv Ther; 2014 Jun; 31(6):621-38. PubMed ID: 24958326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.